Drugs / Crobenetine
Crobenetine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02273466 | Feb → Apr 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02269202 | Feb → Apr 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02269215 | Jan → Sep 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02268136 | Apr → Dec 1999 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02251197 | Jul 2001 → Oct 2002 | stroke disorder | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crobenetine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02273466 ↗ |
| Known as | BIII 890 CL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269215 ↗ |
| Known as | Crobenetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039733 ↗ |
| Modality | Small molecule | — CHEMBL3039733 ↗ |
| Route | Intravenous | “after intravenous infusion” NCT02251197 ↗ |